STOCK TITAN
  1. Home
  2. Sec-filings
  3. CORT
  4. [Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity

Corcept Therapeutics (CORT) CBO reports 17,530-share stock gifts and trust holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Corcept Therapeutics Inc’s Chief Business Officer, Gary Charles Robb, reported several bona fide gift transactions in the company’s common stock on August 12, 2026. He made a gift disposition of 11,530 shares, leaving 13,551 shares held directly, including unvested restricted stock awards. He also reported gifts of 3,000 shares to each of two custodial accounts for his children, which are reported as indirect holdings. Separately, an additional 49,716 shares are held indirectly through the Gary Charles Robb TTE Robb Revocable Trust.

Positive

  • None.

Negative

  • None.
Insider Robb Gary Charles
Role Chief Business Officer
Type Security Shares Price Value
Gift Common Stock F1 11,530 $0.00 $0.00
Gift Common Stock F2 3,000 $0.00 $0.00
Gift Common Stock F3 3,000 $0.00 $0.00
holding Common Stock F4 -- -- --
Holdings After Transaction: Common Stock — 13,551 shares (Direct); Common Stock — 15,571 shares (Indirect, Custodial Account for Child); Common Stock — 49,716 shares (Indirect, Gary Charles Robb TTE Robb Revocable Trust)
Footnotes (4)
  1. F1. Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. F2. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
  3. F3. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
  4. F4. These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.
Direct gift disposition 11,530 shares of Common Stock Bona fide gift on August 12, 2026 from direct holdings
Direct holdings after gift 13,551 shares of Common Stock Direct ownership following the 11,530-share gift, including unvested RSAs
Gifts to custodial accounts 3,000 shares + 3,000 shares of Common Stock Bona fide gifts to two child custodial accounts on August 12, 2026
Trust indirect holding 49,716 shares of Common Stock Held by Gary Charles Robb TTE Robb Revocable Trust, reported as indirect ownership
Unvested restricted stock awards 251, 224, 499, 776 shares Unvested RSAs granted on Sept 2, 2025; Dec 1, 2025; Mar 2, 2026; Jun 1, 2026
Gift transaction price $0.0000 per share Per-share transaction price for reported bona fide gifts
bona fide gift financial
"transaction_code_description: "Bona fide gift" for multiple stock transfers"
A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.
restricted stock awards financial
"Includes shares underlying unvested restricted stock awards granted to the Reporting Person"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
Uniform Transfers to Minors Act financial
"custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian"
Revocable Trust financial
"held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

FAQ

What insider transactions did Corcept Therapeutics (CORT) report on August 12, 2026?
Corcept Therapeutics’ Chief Business Officer, Gary Charles Robb, reported three bona fide gift transactions of common stock on August 12, 2026, plus an updated indirect trust holding of 49,716 shares.

How many Corcept Therapeutics (CORT) shares did Gary Charles Robb gift from his direct holdings?
Gary Charles Robb made a bona fide gift of 11,530 shares of Corcept common stock from his direct holdings, leaving 13,551 shares directly owned, which include several unvested restricted stock awards.

What indirect holdings did Gary Charles Robb report in Corcept Therapeutics (CORT) stock?
He reported 3,000 shares held in each of two custodial accounts for his children and an indirect holding of 49,716 shares through the Gary Charles Robb TTE Robb Revocable Trust.

Are the Corcept Therapeutics (CORT) insider transactions sales or gifts?
All reported transactions with a code “G” are described as bona fide gifts of Corcept common stock, not open-market sales or purchases, and are shown at a $0.0000 per-share transaction price.

What unvested restricted stock awards does Gary Charles Robb hold in Corcept Therapeutics (CORT)?
His direct holding of 13,551 shares includes 251, 224, 499, and 776 shares underlying unvested restricted stock awards granted on September 2, 2025; December 1, 2025; March 2, 2026; and June 1, 2026, respectively.

When will Gary Charles Robb’s Corcept (CORT) restricted stock awards vest?
The filing states that 100% of the shares underlying each restricted stock award will vest on the one-year anniversary of the grant date, provided Gary Charles Robb satisfies specified requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Robb Gary Charles
(Last)(First)(Middle)
C/O CORCEPT THERAPEUTICS INCORPORATED
101 REDWOOD SHORES PARKWAY
(Street)
REDWOOD CITY CALIFORNIA 94065
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Business Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/12/2026G11,530D$0.0013,551(1)D
Common Stock08/12/2026G3,000A$0.0015,571ICustodial Account for Child(2)
Common Stock08/12/2026G3,000A$0.0015,571ICustodial Account for Child(3)
Common Stock49,716IGary Charles Robb TTE Robb Revocable Trust(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
2. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
3. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
4. These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.
Remarks:
The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for Gary Charles Robb08/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR